Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Regenecare** is an MPM Medical topical wound-care hydrogel product name that has been used for lidocaine-containing formulations. The current OTC-labeled **RegeneCare HA** formulation contains lidocaine hydrochloride 2% as its active pharmaceutical ingredient; lidocaine produces local analgesia by reversibly blocking voltage-gated sodium channels in peripheral sensory nerves. Its hydrogel vehicle contains ingredients including aloe vera, collagen, and sodium hyaluronate to support a moist skin or wound environment. The labeled OTC use is temporary relief of pain and itching associated with minor burns, sunburn, minor cuts, scrapes, insect bites, and minor skin irritations. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c3eec066-38e8-4617-b34d-2f72ffb7a324))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Regenecare.